Treatment with IACS-010759, a mitochondrial complex I inhibitor, improved survival and inhibited BM formation in mice resistant to BRAF/MEK inhibitors.39 Similar trends were seen in BM from lung, breast, and renal cancers, indicating increased OXPHOS and sensitivity to IACS-010759.40 Notably, in our study, many DEGs within the OXPHOS pathway were specifically associated with mitochondrial complex I (Supplementary Figure 7A). Here, MAP2K7 is linked to renal carcinoma.